Author:
Jones P. H.,Farmer J. A.,Cressman M. D.,Mckenney J. M.,Wright J. T.,Proctor J. D.,Berkson D. M.,Farnham D. J.,Wolfson P. M.,Colfer H. T.,Rackley C. E.,Sigmund W. R.,Schlant R. C.,Arensberg D.,Mcgovern M. E.
Subject
Cardiology and Cardiovascular Medicine,General Medicine
Reference21 articles.
1. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens;Mosley;J Lipid Res,1989
2. Fujita H, Uno Y, Inazu A, Kajinami K, Takeda M, Koizumi J, Mabuki H, Takeda R, HOKURIKU FH-CHD Study Group: Long-term (2 years) treatment of heterozygous familial hypercholesterolemia with CS-514 (pravastatin), an inhibitor of 3-hydroxy-3 methylglutaryl coenzyme A reductase (abstract). Proc 8th International Symposium on Atherosclerosis. Rome, Italy, October 9 to 13, (1988) 272
3. Pravastatin: A tissue selective once-daily HMG-CoA reductase inhibitor in the treatment of primary hypercholesterolemia (abstr);Hunninghake;J Am Coll Cardiol,1988
4. Effects of CS-514, a new inhibitor of HMG-CoA reductase, on plasma lipids, lipoproteins, and apoproteins in patients with primary hypercholesterolemia;Kazumi;Horm Metab Res,1986
5. Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia
Cited by
57 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献